|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_NoncurrentFinancialAssetAcquisitionAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Evet (Yes)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
25.10.2023
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_BoardDecisionDateForAcquisition|
|
|
25/10/2023
|
|||||||
|
oda_WereMajorityOfIndependentBoardMembersApprovedTheBoardDecisionForAcquisition|
|
|
Yes
|
|||||||
|
oda_TitleOfNoncurrentFinancialAssetAcquired|
|
|
Neo Auvra Dijital Sağlık ve Biyonik Teknolojileri ve Hizmetleri Sanayi ve Ticaret A.Ş.
|
|||||||
|
oda_FieldOfActivityNoncurrentFinancialAssetWhoseSharesWereAcquired|
|
|
Holistic digital health softwares
|
|||||||
|
oda_CapitalOfNoncurrentFinancialAsset|
|
|
250.000
|
|||||||
|
oda_AcquirementWay|
|
|
Sermaye Artırımı Yoluyla Edinim (Capital Increase)
|
|||||||
|
oda_DateOnWhichTheTransactionWasWillBeCompleted|
|
|
02.02.2024
|
|||||||
|
oda_AcquisitionConditions|
|
|
Diğer (Other)
|
|||||||
|
oda_DetailedConditionsIfItIsATimedPayment|
|
|
-
|
|||||||
|
oda_NominalValueOfSharesAcquired|
|
|
50.000
|
|||||||
|
oda_PurchasePricePerShare|
|
|
20 USD
|
|||||||
|
oda_TotalPurchasingValue|
|
|
1.000.000 USD
|
|||||||
|
oda_RatioOfNewSharesAcquiredToCapitalOfNoncurrentFinancialAsset|
|
|
20
|
|||||||
|
oda_TotalRatioOfSharesOwnedInCapitalOfNoncurrentFinancialAssetAfterTransaction|
|
|
32,39
|
|||||||
|
oda_TotalVotingRightRatioOwnedInNoncurrentFinancialAssetAfterTransaction|
|
|
32,39
|
|||||||
|
oda_RatioOfNoncurrentFinancialAssetAcquiredToTotalAssetsInLatestDisclosedFinancialStatementsOfCompany|
|
|
0,29
|
|||||||
|
oda_RatioOfTransactionValueToSalesInLatestAnnualFinancialStatementsOfCompany|
|
|
0,04
|
|||||||
|
oda_EffectsOnCompanyOperations|
|
|
Positive impact is expected
|
|||||||
|
oda_DidTakeoverBidObligationArised|
|
|
Hayır (No)
|
|||||||
|
oda_WillExemptionApplicationBeMadeIfTakeoverBidObligationArised|
|
|
Hayır (No)
|
|||||||
|
oda_TitleNameSurnameOfCounterParty|
|
|
-
|
|||||||
|
oda_IsCounterPartyARelatedPartyAccordingToCMBRegulations|
|
|
Evet (Yes)
|
|||||||
|
oda_RelationWithCounterPartyIfAny|
|
|
GEN has company's shares
|
|||||||
|
oda_AgreementSigningDateIfExists|
|
|
25/10/2023
|
|||||||
|
oda_ValueDeterminationMethodOfNoncurrentFinancialAsset|
|
|
Negotiation
|
|||||||
|
oda_DidValuationReportBePrepared|
|
|
Düzenlenmedi (Not Prepared)
|
|||||||
|
oda_ReasonForNotPreparingValuationReportIfItWasNotPrepared|
|
|
Non obligatory
|
|||||||
|
oda_DateAndNumberOfValuationReport|
|
|
-
|
|||||||
|
oda_TitleOfValuationCompanyPreparedReport|
|
|
-
|
|||||||
|
oda_ValueDeterminedInValuationReportIfExists|
|
|
-
|
|||||||
|
oda_ReasonsIfTransactionWasntWillNotBePerformedInAccordanceWithValuationReport|
|
|
-
|
|||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
-Unofficial Translation- Convertible Loan Agreement signed between Neo Auvra Dijital Sağlık ve Biyonik Teknolojileri ve Hizmetleri Sanayi ve Ticaret A.Ş.'ye ("Neo Auvra") which GEN has 12,39% shares with a loan amount calculated Turkish Liras equivalent to USD 1.000.000,00 (One Million US Dollars) was disclosed to the public on 25.10.2023. ( https://www.kap.org.tr/en/Bildirim/1209443 ) According to the Convertible loan agreement maturity of the loan is determined as 01.01.2024 and it was disclosed that after maturity conversion to shares transaction will be completed Conversion to shares transaction was completed on Neo Auvra'a general assembly made on 02.02.2024. Towards, GEN will acquire A Group Shares equal to the 20,00% of the Neo Auvra's total shares. As a result of the subjected transaction GEN, will be owner of the A Group shares equal to the 20,00% of the company's total shares according to the convertible loan agreement signed on 25.10.2023. GEN, already owner of the C Group Shares equal to the 12,39% of the total shares of the company. After the registration of General Meeting and completion of the share issuance transactions GEN will be the owner of the 32,39% of Neo Auvra. |
||||||||